Favipiravir (Avigan) Powder
Product name: Favipiravir / Avigan /Favilavir
CAS:259793-96-9 Chemical formula:C5H4FN3O2
Favipiravir, also known as T705, or Avigan, is a pyrazine carboxamide derivative with activity against RNA viruses.
It is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses, and alphaviruses. Activity against enteroviruses and the Rift Valley fever virus has also been demonstrated.
The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase. Favipiravir(T-705) does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them. In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.
In February 2020, Favipiravir was being studied in China for experimental treatment of the emergentCOVID-19 (novel coronavirus disease).]On 17 March 2020, Chinese officials suggested the drug had been effective in treating COVID in Wuhan and Shenzhen.
6-FLUORO-3-HYDROXYPYRAZINE -2-CARBOXAMIDE T-705 5-fluoro-2-oxo-1H-pyrazine-3- carboxamide
H-NMR is consistent with proposed structure-NMR
A mass spectrum is consistent with the proposed structure
The retention time of the main peak in sample preparation should be comparable with the retention time of the main peak in reference standard preparation
Maximum single impurity≤0.1%
98.0%~102.0%on the dried basis
As the largest bulk Favipiravir manufacturer, with local GMP certificates, we promised that all the materials meet the above specifications.
Function of Fabirovir
Activity against enteroviruses and the Rift Valley fever virus has also been demonstrated. The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase. Favipiravir does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them. In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.S.
China has completed the clinical research of Favipiravir, an antiviral drug that has shown good clinical efficacy against the novel coronavirus disease (COVID-19), according to an official Tuesday.
Favipiravir, the influenza drug which was approved for clinical use in Japan in 2014, has shown no obvious adverse reactions in the clinical trial, said Zhang Xinmin, director of the China National Center for Biotechnology Development under the Ministry of Science and Technology, at a press conference.
It has been recommended to medical treatment teams and should be included in the diagnosis and treatment plan for COVID-19 as soon as possible, Zhang said.